6533b86ffe1ef96bd12ce8aa
RESEARCH PRODUCT
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke
Cipollone FToniato EMartinotti SFazia MIezzi ACuccurullo CPini BUrsi SVitullo GMaurizio AvernaArca MMontali ACampagna FUcchino SSpigonardo FTaddei SVirdis ACiabattoni GNotarbartolo ACuccurullo FMezzetti AIdentification Of New Elements Of Plaque Stability Ines Study Groupsubject
MalePathologySettore MED/09 - Medicina InternaArteriosclerosisCarotid StenosiMyocardial InfarctionInfarctionProstacyclinGastroenterologyCohort StudiesCerebrovascular AccidentrteriosclerosiRisk FactorsGenotypeMedicineCarotid StenosisProspective StudiesMyocardial infarctionMembrane ProteinStrokebiologyGeneral MedicineMiddle AgedIsoenzymesStrokePhenotypeMatrix Metalloproteinase 9Matrix Metalloproteinase 2FemaleHumanmedicine.drugmedicine.medical_specialtyGenotypeArteriosclerosiInternal medicineDiabetes mellitusHumansPolymorphism Geneticbusiness.industryC-reactive proteinProstaglandin-Endoperoxide SynthaseMembrane Proteinsmedicine.diseaseEpoprostenolIsoenzymeProspective StudieAtheromaCyclooxygenase 2Prostaglandin-Endoperoxide Synthasesbiology.proteinCohort Studiebusinessdescription
CONTEXT: Myocardial infarction (MI) and ischemic stroke are thought to be caused by matrix digestion by metalloproteinases (MMPs) leading to rupture of atherosclerotic plaques. Production of macrophage MMP-2 and MMP-9 is induced by cyclooxygenase 2 (COX-2) and prostaglandin E(2) synthesis. Although COX-2 expression may be genetically determined, the relation between COX-2 polymorphisms and the risk of MI and stroke is unclear. OBJECTIVE: To investigate the relationship between the -765G-->C polymorphism of the COX-2 gene and clinically evident plaque rupture. DESIGN, SETTING, AND PARTICIPANTS: Prospective, matched case-control study conducted between March 2002 and October 2003 among 864 patients with first MI or atherothrombotic ischemic stroke and 864 hospitalized controls. The groups were matched for age, sex, body mass index, smoking, hypertension, hypercholesterolemia, and diabetes. The -765G-->C variant of the COX-2 gene was genotyped by restriction endonuclease digestion of polymerase chain reaction products. MAIN OUTCOME MEASURES: Presence of the -765G-->C polymorphism of the COX-2 gene; COX-2, MMP-2, and MMP-9 expression and activity in plaques and in peripheral monocytes; urinary 6-keto PGF1alpha (marker of endothelial prostacyclin); and endothelium-dependent and -independent forearm blood flow vasodilation. RESULTS: The prevalence of -765GC was 2.41 times higher among controls than among cases (43.3% vs 17.9%; PC polymorphism did not affect endothelial prostacyclin biosynthesis or endothelium-dependent vasodilation in vivo. In subgroup analyses (n = 224 cases), serum high-sensitivity C-reactive protein was significantly lower in patients carrying the -765C allele (mean [SD], 0.78 [0.1] vs 2.56 [0.4] mg/L; P =.04). CONCLUSIONS: We found that the -765G-->C polymorphism of the COX-2 gene is associated with a decreased risk of MI and stroke. Detection of this genotype may be useful for predicting genetic risk of MI and stroke.
year | journal | country | edition | language |
---|---|---|---|---|
2004-01-01 |